THE ROLE OF OXIDATIVE STRESS IN THE PATHOGENESIS OF RETINOPATHY OF PREMATURITY

Ph.D. thesis

Andrea Papp, MD

Department of Ophthalmology
Faculty of Medicine
University of Szeged, Hungary
Head: Prof. Lajos Kolozsvari, MD, PhD



TABLE OF CONTENTS

l. I	List of papers related to the subject of the thesis	4
2. <i>A</i>	Abbreviations	5
3. S	Summary	6
4. I	ntroduction	10
	4.1 Retinopathy of prematurity	10
	4.1.1. History	10
	4.1.2. Risk factors	11
	4.2. Oxygen Radical Disease of Prematurity	12
	4.2.1. Free oxygen radicals	12
	4.2.2. The defense system against oxygen radicals	12
	4.2.3. Oxidative stress and the preterm newborn	13
	4.3. Similarities between the human retina and red blood cells	14
	4.3.1. Susceptibility to oxidative stress	14
	4.3.2. Similarities in structure, metabolism and antioxidant	
	defense	14
	defense	
5.		15
	4.4. Aims of the thesis	15 16
	4.4. Aims of the thesis	15 16
	4.4. Aims of the thesis	15 16 16
	4.4. Aims of the thesis	15 16 16 16
	4.4. Aims of the thesis Patients and methods 5.1. Patients 5.1.1. Retrospective study 5.1.2. Prospective study	15 16 16 17
	4.4. Aims of the thesis Patients and methods 5.1. Patients 5.1.1. Retrospective study 5.1.2. Prospective study 5.1.3. Maternal examinations	15 16 16 17 18
	4.4. Aims of the thesis Patients and methods 5.1. Patients 5.1.1. Retrospective study 5.1.2. Prospective study 5.1.3. Maternal examinations 5.1.4. Ethical considerations	15 16 16 17 18
	4.4. Aims of the thesis Patients and methods 5.1. Patients 5.1.1. Retrospective study 5.1.2. Prospective study 5.1.3. Maternal examinations 5.1.4. Ethical considerations 5.2. Methods	15 16 16 17 18 18
	4.4. Aims of the thesis Patients and methods 5.1. Patients 5.1.1. Retrospective study 5.1.2. Prospective study 5.1.3. Maternal examinations 5.1.4. Ethical considerations 5.2. Methods 5.2.1. Biochemical assays	15161617181818
	4.4. Aims of the thesis Patients and methods 5.1. Patients 5.1.1. Retrospective study 5.1.2. Prospective study 5.1.3. Maternal examinations 5.1.4. Ethical considerations 5.2. Methods 5.2.1. Biochemical assays 5.2.2. Statistical analysis	1516161718181818

	6.1.2.	APH challenge and response: GS	H stability test and
		hemoglobin oxidation	22
	6.1.3.	Blood selenium concentration	22
(6.2. Pros	pective study	22
	6.2.1.	Individual parameters: gestational age	and birth weight22
	6.2.2.	GSH redox system	23
	6.2.3.	Concentrations of free sulfhydryl grou	ips in the prematures
		and their mothers	23
	6.2.4.	Blood selenium concentrations in the p	orematures and their
		mothers	23
	6.2.5.	The effect of vitamin E administration	on the concentrations
		of free sulfhydryl groups and selenium	1 levels23
	6.2.6.	Plasma concentrations of antioxidant v	vitamins: E and A24
	6.2.7.	Plasma ferrintin levels	24
7.	Discussion	on	25
8.	Conclusions39		
9.	Message		41
10.	Acknowledgements43		
11.	References4		

1. LIST OF PAPERS RELATED TO THE SUBJECT OF THE THESIS

- I. Papp, A., Nemeth, I., Karg, E., Papp, E.: Glutathione status in retinopathy of prematurity. Free Rad. Biol. Med., Vol 27, Nos .7/8, pp.738-743, 1999.
- II. Papp, A., Nemeth, I., Pelle, Zs.: A retrospective ophthalmological and biochemical study on the antioxidant defense capacity of patients suffering from retinopathy of prematurity. In: Mozsik Gy., Emerit I., Feher J., Matkovics B., Vincze A. (Eds.): Oxygen Free Radicals and Scavengers in the Natural Sciences, Akademiai Kiado, Budapest, pp. 203, 1993.
- III. Papp, A., Nemeth, I., Pelle, Zs., Tekulics, P.: A one-year ophthalmical and biochemical follow-up study on prematures with high risk of retinopathy. In: Mozsik Gy., Emerit I., Feher J., Matkovics B., Vincze A. (Eds.): Oxygen Free Radicals and Scavengers in the Natural Sciences, Akademiai Kiado, Budapest, pp. 199, 1993.
- IV. Papp, A., Nemeth, I., Pelle, Zs.: A retrospective, biochemical study on the antioxidant defense capacity of patients suffering from Retinopathy of Prematurity. Orv. Hetil., 134/19: 1021-1026, 1993.
- V. Papp, A., Nemeth, I., Pelle, Zs., Tekulits, P.: A prospective, biochemical study on the antioxidant defense capacity of patients suffering from Retinopathy of Prematurity. Orv. Hetil. 201: 201-205, 1997.
- VI. Papp, A., Nemeth, I., Pelle, Zs., Tekulics, P.: Antioxidant vitamins and iron-pool in preterm infants suffering from Retinopathy of Prematurity. Opht. Hung. (Szemeszet), 132/1:51-55, 1995.

2. ABBREVIATIONS

APH – acetylphenylhydrazine

G6PD - glucose-6-phosphate-dehydrogenase

GSH – reduced glutathione

GSSG - oxidized glutathione

GSSG/GSH - glutathione redox ratio

GSH-Px - gluathione peroxidase

GSH-Red – glutathione reductase

Hb - hemoglobin

NEM – **n-e**thyl**m**aleimide

RBCs - red blood cells

ROP – retinopathy of prematurity

Se - Selenium

SOD – superoxide dismutase

Cat - catalase

IRBP – interstitial retinol binding protein

-SH - free sulphydryl groups

EPO – erythropoietin

3. SUMMARY

Background: Retinopathy of Prematurity (ROP) is one of the leading causes of childhood blindness. As a result of the improved and careful management in the neonatal intensive care units the survival rate of very small premature infants dramatically increased during the last two decades. A new ROP epidemic started among the very low birth weight and high-risk preterm infants. The etiology ROP is multifactorial and the pathomechanism is still not clear. Better understanding of the environmental and individual factors that cause retinal neovascularisation and lead to this disabling condition requires further investigation. One of the proposed pathomechanisms of ROP is oxygen radical injury. It occurs when the body's natural antioxidant capacity is overwhelmed by the free oxygen radicals produced during the perinatal period.

Objective: On the hypothesis that a special susceptibility of prematures with ROP does exist (e.g. some kind of trace element or vitamin deficiency causing decreased activity of antioxidant enzymes), retrospective and prospective studies were carried out. The similarity between the erythrocyte (RBC) membrane and the immature retina both in their structure and antioxidant defense systems led us to study RBC as indicator of the oxidative status of patients.

Study design and patients

Retrospective study

Supposing that premature infants may have defects in their antioxidant systems which can be detected later, even in childhood, a retrospective study of 50 ROP patients of different ages (between 6 weeks and 6 years), who had been born prematurely (gestational age: 28.7±1.3 weeks; birth

weight: 1210±313 g; mean±SD) and were suffering from different stages of ROP (stage 2-5) was carried out.

Prospective study

After confirming the presence of the diminished antioxidant defense capacity in our retrospective study, a prospective study was planned. Our one-year study was carried out on 60 premature infants (gestational age: 32.8±3.1 weeks, range: 26-35 weeks); birth weights under 2000 g (mean: 1529±302 gs, range: 980-1840) admitted immediately after birth to the Perinatal Intensive Care Unit of the Department of Pediatrics for oxygen therapy (FIO₂ >0.6 longer than 24 hrs). In our prospective study a close ophthalmological follow-up was provided in order to monitor the presence and the outcome of ROP. Both the ROP screening and the biochemical tests were started at the age of 6 weeks. We examined the biochemical parameters of available mothers as well, supposing the mother's responsibility in determining the infant's antioxidant defense capacity, via her nutritional status (e.g. vitamin and trace element supply) and lifestyle (e.g. smoking) during pregnancy.

Methods: The ratio of oxidized/reduced glutathione (GSSG/GSH) was used as a parameter of *in vivo* oxidative stress. The degree of GSH stability after an *in vitro* oxidative insult and the presence and amount of hemoglobin oxidation products (methemoglobin, hemichrome) reflected the antioxidant protective capacity of RBCs. Blood selenium levels were measured by fluorometry. Plasma concentrations of free sulphydryl groups were determined by a spectrophotometric method.

Plasma concentrations of vitamin E and vitamin A were measured simultaneously by a HPLC method. Radioimmunassay was performed to determine ferritin concentrations.

Results: 1) A significant increase in the GSSG/GSH as a specific sign of acute oxidative stress was only seen in the youngest patients (<3 months).

2) The compromised antioxidant defense capacity could be detected in all

ROP patients even in childhood following an in vitro oxidative stress. 3) The very low selenium levels in all ROP patients both in the retrospective

and prospective studies indicated a reduced GSH-peroxidase activity.

The same tendency was seen in the mothers. 4) The concentrations of free sulphydryl groups in the plasma were significantly lower in ROP patients; maternal levels showed the same relationship. 5) Marked decrease of plasma vitamin E concentrations were determined both in our ROP patients and in their mothers. 6) Vitamin E supplementation seems to have positive effect on prevention of ROP progression: both the ophthalmological and selenium status improved after per os vitamin E administration. 7) Plasma vitamin A concentrations were lower in those premature infants suffering from ROP 8) Ferritin concentration, which is an indicator of the body's iron load, was much higher in ROP patients than in their mothers.

Conclusions: 1) The RBC glutathione redox ratio is an adequate parameter to reflect the oxidative stress in the acute phase of ROP. 2) ROP may develop in those patients who have reduced antioxidant defense capacity (genetic or acquired). 3) Selenium depletion in Hungary might be an important predisposing factor to ROP. 4) The fact that during our screening for ROP we could only diagnose 5 cases of mild ROP from 60 high-risk premature infants, leads us to the conclusion that the management of preterm infants at the Perinatal Intensive Care Unit of our University and the secondary treatment at the Children's Hospital is very careful. 5) The close correlation found between the low free sulphydryl group and selenium levels of mothers and babies suggest that supplementation with sulfur containing aminoacids (e.g. methionin,

cystein) and selenium during pregnancy would improve the antioxidant capacity of premature infants. 6) The very low vitamin E levels measured both in our ROP patients and in their mothers suggest that an 'antioxidant cocktail' described in literature (containing Se and vitamin E) given to the high-risk mothers before delivery might be useful in the prevention of ROP. 7) According to our results, per os vitamin E supplementation seems to have a positive effect on the prevention of ROP progression. Because of the potential harmful side effects, however, vitamin E treatment must be closely monitored by repeated measurements of plasma vitamin E level. 8) The fact that in spite of the mothers' iron deficiency, fully saturated iron pools were detected in their preterm infants, leads us to the conclusion that during the first 6 weeks of life iron overload occurs and might be one of the main factors leading to Retinopathy of Prematurity.

4. INTRODUCTION

4.1. Retinopathy of prematurity

4.1.1 History

Retinopathy of prematurity (ROP) is a disease of the incompletely vascularized immature retina. characterized by retinovitreal neovascularization and retinal scarring. In the most severe cases retinal detachment can occur, leading to serious visual disability and even complete blindness [26, 76]. The disease was first reported in 1942 by Terry [113]. The cause of the first ROP epidemic appeared to be the excess oxygen, administered in high concentrations to premature infants in order to keep them alive. ROP was the first disease entity, at least in neonatology, which was referred to the effect of hyperoxia, thus, the original classical manifestation of oxygen toxicity due to excessive oxygen administration in premature infants [14].

Although oxygen therapy has subsequently been restricted and is now precisely controlled in modern neonatal intensive care units, we are in the midst of a second epidemic of a blinding disease which - many anticipated - would have been disappeared by now. *Phelps* estimated the number of ROP-blinded infants and found it comparable to the number of annual cases recorded at the peak of the first epidemic [79]. Despite the use careful oxygen monitoring, other investigators have noted the continued occurrence of new cases of ROP [29,37, 68,84]. Thus, ROP still remains one of the major causes of childhood blindness.

The increased survival rate of the very low birth weight infants and the special characteristics of retinal development can provide a possible explanation to the question why ROP never completely vanished. The inner retinal vasculature develops from spinite very which are the

precursor cells of the retinal endothelial cells. Spindle cells are largely in place by the 16th week of gestation [50]. The central retinal artery grows through the optic nerve, branching into arterioles that advance centrifugally across the retinal surface. By 32 weeks of gestational age, peripheral retinal vascularisation is taken place in most infants but may not be complete until 40 weeks of gestation [33]. As a result of the improved obstetric techniques and modern technologies of the perinatal intensive care, even extremely immature infants are able to survive, requiring more of their retinal vasculature to develop ex utero, often in the environment of a neonatal intensive care unit [23,29-31].

4.1.2. Risk Factors

Apart from immaturity and oxygen exposure approximately 50 more recognized risk factors have been reported [95]. Numerous studies have attempted to identify and give relative significance to different risk factors that are associated with the occurrence of ROP. However, in spite of the long list of the recognized ethiological factors, such as hyperoxia, hypoxia, immaturity (low birth weight and gestational age), low APGAR scores, apnoe, anemia, blood transfusions, sepsis, light exposition, lactic acidosis [44], administration of xanthine derivates, vitamin E deficiency, multiple gestation, advanced maternal age, diabetes, preeclampsia, toxemia, amnionitis, premature rupture of membranes, bleeding, administration of \(\beta_2 \) blockers, antihistamines in late pregnancy etc., the pathogenesis of this potentially blinding disease is still unclear. [6,7,8,12,33,37,47,67,81,95,121] ROP has even been documented among infants with various congenital malformation syndromes, such as anencephaly, trisomy 18, cri-du-chat syndrome, supporting the theory of intrauterine causation [27,37]. The possible role of genetics has been supported by molecular genetic studies: some infants with advanced retinopathy have missens mutations in the gene for Norrie's disease [98]. The occurrence of ROP in prematures who received no oxygen treatment at all [27] or in mature newborns with cyanotic congenital heart disease [48] suggested the presence of further, as yet unknown risk factors in the pathogenesis. Logistic regression analysis has demonstrated that the gestational age and the frequency of blood transfusions are the only parameters independently associated both with the occurrence of ROP and with its severity [20,37,45,89].

4.2. Oxygen Radical Disease of Prematurity

4.2.1. Free oxygen radicals

Free radicals are compounds with one or more unpaired electrons. They are highly reactive and can initiate chain reactions, which form new free radicals. Oxygen free radicals like the superoxide radical (O₂-), the hydroxyl radical (OH-) and the singlet oxygen can damage membranes by lipid peroxidation, inactivating enzymes, and damaging disulfide bonds of proteins. They can even cause DNS injury [28,90].

Free radicals are created in the human body even in the course of the normal metabolism but also by activated leukocytes as a part of the inflammatory defense mechanism against microorganisms. During oxygen treatment, phototherapy, blood transfusions, etc. they are generated in increased quantity.

4.2.2. The defense system against oxygen radicals

The antioxidant defense mechanism of the body includes cellular and extracellular enzymes such as superoxide dismutase (SOD), catalase (Cat), glutathione reductase (GSH-Red) and glutathione peroxidase (GSH-Px). GSH-Px is selenium (Se) dependent and therefore selenium plays an important role in the natural defense against free radicals. The other important free radical scavengers are: glutathione, free sulfhydril groups, vitamins E and C, caroteinoids in addition to serum albumin and metabolic products such as uric acid and bilirubin.

4.2.3. Oxidative stress and the preterm newborn

Oxidative stress occurs when the production of free radicals overwhelms the body's natural antioxidant defence systems, resulting in oxidative damage of the cells [101]. All infants, regardless of gestational age, have shown evidence of oxidative damage during the first few days after birth [90].

In humans and most of the animals studied, antioxidant enzymes are expressed in high concentration only at the end of gestation in preparation of the relatively hyperoxic extrauterine environment [86] Thus, preterm infants with their immature enzymes are pariculary vulnerable to oxidative stress. Genetic variability, maternal oxidative stress, lifestyle (e.g. smoking, nutrition) and maternal antioxidant capacity are all contributing factors which determine how the infant will withstand the stress of being born into a relatively hyperoxic environment (compared to the intrauterine experience). After birth, once the antioxidant defence capacity of the premature infant is overwhelmed, they become susceptible to several neonatal diseases. The pathogenic role of oxygen toxicity has been recognized in retinopathy of prematurity (ROP), respiratory distress syndrome (RDS), bronchopulmonary dysplasia (BPD), necrotizing enterocolitis (NEC), subependymal and intraventricular hemorrhage (IVH) and persistent ductus arteriosus Botalli (PDA). Saugstad has proposed the term 'Oxygen Radical Disease in Neonatology' to make it clear that these conditions may be different manifestations of the same disease [90]. Because of the greater incidence

of these disorders in preterm infants with deficient antioxidant systems, a better name for this disorder, according to Sullivan, is 'Oxygen Radical Disease of Prematurity' [106].

4.3. Similarities between the human retina and red blood cells

4.3.1. Susceptibility to oxidative stress

The retina is one of the organs most directly exposed to high oxygen tension, and the endothelial cells of its microvessels as well as the cells of the retinal epithelium are highly susceptible to oxidative injury. Red blood cells (RBC) are frequently exposed to oxidative stress as well. They take up oxygen in the lungs at high oxygen tension, contain the greatest part of the body's iron in hemoglobin (Hb), and during the permanent autooxidation of Hb, active oxygen species are generated in them. RBCs handle the permanent intracellular oxidative stress through the combined activities of SOD, Cat the glutathione-dependent defence system. The most important intracellular antioxidant, glutathione, is present mainly in a reduced form (GSH), and at a far lower concentration in an oxidized form (GSSG) [103]. The efficient recycling of GSSG to GSH through the interrelated enzyme systems: glutathione reductase (E.C. 1.6.4.2) and glucose-6-phosphate-dehydrogenase (G6PD; E.C. 1.1.1.49) is a requirement for adequate antioxidant protection [103].

4.3.2. Similarities in structure, metabolism and antioxidant defence

There are several similarities between the human retina and the red blood cells (RBCs): their membrane structures (very long chain unsaturated fatty acids with a marked susceptibility to oxidative insult), their metabolism (high demands for glucose and oxygen) and their antioxidant defense mechanisms (glutathione-dependent defense systems,

Gsh-Px, SOD...etc.) show marked similarities [22,82].

Therefore, the oxidative status of the RBCs can be used as a biological index of retinal oxidative injury [80,116]. On the other hand, there is increasing evidence that the efficient glutathione recycling of the RBCs is involved in the protection against oxidative damage not only of the RBCs themselves, but also of other tissues (e.g. lung) in premature infants [19,63-65,96].

4.4. Aims of the thesis

4.4.1. Retrospective study

Based on the overview of the relevant literature we supposed that a special susceptibility of prematures with ROP does exist (e.g. some kind of trace element or vitamin deficiency causing decreased activity of antioxidant enzymes), which can be detected later, even in childhood. Based on this hypothesis a retrospective study of patients of different ages (born prematurely) suffering from different stages of ROP was carried out [71-73].

4.4.2. Prospective study

After confirming the presence of a diminished antioxidant defense capacity in our retrospective study, a prospective study was planned. We carried out a one-year study on previously oxygen-treated, low birth weight premature infants, following them from the age of 6 weeks until their first birthday. In our prospective study a close ophthalmological follow-up was provided in order to monitor the presence and the final outcome of ROP [71, 74-75].

4.4.3. Maternal examinations

Maternal oxidative stress, lifestyle (e.g. smoking, nutrition) and maternal antioxidant defense capacity are all important factors which determine how the infant will withstand the oxidative stress after birth. Therefore, our third aim was to find the maternal factors contributing to the special susceptibility of ROP patients to free radicals. This study was carried out to assess the relationship between maternal and fetal levels of different antioxidants, vitamins and trace elements [71, 74-75].

5. PATIENTS AND METHODS

5.1 Patients

5.1.1. Retrospective study

We studied 50 ROP patients of different ages (between 6 weeks and 6 years), who had been born prematurely (gestational age: 28.7±1.3 weeks; birth weight: 1210±313 g; mean±SD). 12 patients were studied at the time of their ROP screening at the Perinatal Intensive Care Unit. 14 infants and 24 children suffering from a visual handicap due to preceding ROP were studied at the ophthalmological follow-up clinic. Their biochemical data were compared with those of controls of similar age (n=56), who had also been born prematurely (gestational age: 29.2±1.5 weeks; birth weight: 1305±283g), and treated with the same therapeutic principles, including oxygen therapy, but who had recovered without bronchopulmonary dysplasia or ROP [71-73].

The first ophthalmological examinations were carried out at the postconceptional age of 34-36 weeks or at 6 weeks postnatal age, whichever came first. Indirect ophthalmoscopy was used after pupillary

dilatation to evaluate the severity of the retinal manifestation of ROP. Staging was based on the International Classification of ROP [114].

5.1.2. Prospective study

Our one-year study was carried out in 60 premature infants (gestational age: 32.8±3.1 weeks, range: 26-35 weeks); birth weights under 2000 g (mean: 1529±302 gs, range: 980-1840), admitted immediately after birth to our Perinatal Intensive Care Unit for oxygen therapy (FIO₂ >0.6 longer than 24 hrs) and intensive care. Patients in the control group were, gestational age (33.1±1.1 weeks) and weight-matched (1609±102 gs) premature infants (n= 20) who required only minimal oxygen therapy (FIO2<0.3) [70,74-75].

Ophthalmological examination was first carried out at 34-36 weeks of postconceptional age (postnatal 6.2±1.2 weeks). The ocular investigation was repeated every 1 or 2 weeks thereafter until our patients' first birthday. Direct and indirect ophthalmoscopy was performed, following maximal pupillary dilatation in order to monitor the retinal vascularisation. In some cases, ultrasound was used as well to evaluate the severity of retinal manifestation. ROP staging was based on the International Classification of ROP [114] as follows. Prethreshold ROP stage 1: demarcation line; stage 2: ridge; stage 3: ridge and extraretinal fibrovascular proliferation. The indication for cryotherapy was threshold ROP (stage 3 ROP with 'plus disease') [76,114].

According to their ophthalmological status, patients were divided into 3 groups: 1) ROP free group (n=27; gestational age 33.7± 2.5 weeks; birth weight: 1707±306 g; mean±SD): the fundus was normal. 2) ROP suspect group (n=28, gestational age: 32.3±3.2 weeks; birth weight: 1418±273 g): because of the abnormal tortuosity of retinal vessels and the pale, avascular temporal retinal periphery, this group required special attention, they were given vitamin E (30 mg oral doses twice a week). 3)

Pretreshold ROP group (n=5; gestational age: 29.8±3.2 weeks; birth weight: 1310±330 g; p<0.05): stage 1-2 and 2-3 ROP, different types of junctions were seen between the vascular and avascular part of the retina from a demarcation line to a highly elevated ridge. None of our patients suffered from severe, stage 4-5 ROP.

5.1.3. Maternal examinations

At the time of the first ROP-screening (34-36 weeks postconceptional age or 6 weeks postanatal age, whichever came first), the first biochemical examination was carried out on the infants as well as on 44 mothers [70,74-75].

5.1.4. Ethical Consideration

All of our studies were approved and monitored by the Scientific Committee and the Ethical Council of the University. The research followed the tenets of the Declaration of Helsinki. Informed consent was obtained from the parents. 1.5 ml whole blood was collected over EDTA from a peripheral vein from each subject.

5.2. Methods

5.2.1 Biochemical assays

Highly sensitive and specific separate determinations of GSSG and GSH+GSSG concentrations were carried out using the method described by Nemeth and Boda [65]. This is a combination of standard methods [1,34,103,117] used after validation for accurate determination, especially of GSSG values in the presence of much higher concentrations of GSH (max. 50 times), in the presence of Hb and its oxidation products, and after sample storage.

In order to avoid artifactual oxidation of GSH in blood or in assay conditions, samples for GSSG measurement (25 µl of whole blood collected over EDTA) were hemolyzed within 15 min after venipuncture with cold buffer in the presence of N-ethylmaleimide (NEM; final concentration 0.02 M in 0.01 M phosphate buffer containing 0.005 M EDTA) [117]. The reaction of NEM with GSH results in the formation of a stable complex, which prevents its possible oxidation to GSSG. After incubation with NEM for 60 min at 25 °C metaphosphoric acid (final concentration 3%, w/v) was used to precipitate proteins [103]. Supernatant was stored at -20 °C (max. 6 days) until spectrophotometric determination of GSSG. As NEM is an inhibitor of GSH-Red, it was separated from the supernatant by gel filtration with Sephadex G-10 and controlled by measuring the absorbance of NEM at 315nm [34] immediately before GSSG measurement.

For measuring the total concentration of GSH+GSSG according to Tietze [117], 25 µl of whole blood anticoagulated with EDTA was immediately hemolyzed in 2.5 ml of cold 0.01 M sodium phosphate buffer containing 5 mM EDTA, pH=7.5, and stored at -20 °C until spectrophotometric analysis (max. 6 days). The possible oxidation of GSH to GSSG catalyzed by heme compounds during storage has no influence on the total amount of GSH+GSSG.

The same standard glutathione assay mixture was used for the analysis of GSSG and GSSG+GSH concentrations. Reagents were dissolved in 0.1M sodium phosphate/0.005M EDTA buffer, pH=7.5; the final volumes were 1.0ml. Components were added in the following order: 5,5'-dithio-bis-2-nitrobenzoic acid (DTNB) (0.6 µM), GSSG (0.4 ml of supernatant after NEM removal) or GSH+GSSG (25 µl of hemolysate), glutathione reductase (10µg) and NADPH (0.2 µM). The combined actions of DTNB and NADPH in the presence of GSH-Red result in a reaction cycle the rate of which depends on the concentration of

GSH+GSSG recorded at 412 nm during the first 6 minutes.

GSH (µmol) and GSSG (nmol) concentrations were calculated by using 5-100 nmol GSSG standards and expressed with reference to Hb determined simultaneously by the cyanmethemoglobin method [65]. As the main role of GSH is the protection of Hb, it is necessary to correct the measured GSH for the actual Hb value as described by the authors of standard methods [1,103,117].

The `GSH stability test` according to Beutler [10] was described to measure the capacity of the glutathione redox system to protect Hb after an in vitro oxidative stress. Acetylphenylhydrazine (APH) (0.33 mM) was added to the whole blood sample, together with sufficient glucose. Following incubation at 37 °C for 60 min with APH, RBCs deficient in G6PD, but not the normal ones, suffer a marked fall in GSH level, accompanied by a pronounced Hb oxidation [beutler]. The proportion of oxidized derivatives of Hb (metHb and hemichrome) along with the concentration of GSH before and after APH incubation was determined by the method of Szebeni and Winterbourn [110, 124] and Tietze [117] respectively.

Selenium concentrations in erythrocytes were determined by the diaminonaphthalene fluorometric method described by the Lalonde [53]. After destroying the cell membranes of the washed erythrocytes, the Se content of the RBCs was converted into pieso-selenol complex by adding 2.3 diamino-napthalene (DAN, SIGMA). Fluorescence was measured at 360nm excitation and 520nm emission wavelengths using Hitachi spectroflourometer. Se concentrations were expressed with reference to Hb.

The concentration of free sulfhydryl groups (-SH) in the plasma was determined by a spectrophotometric method described by Koster [49]. The Ellmann's reagent's color change was detected at 412nm.

Concentrations of vitamin E (alpha-tocopherol) and vitamin A (retinol) were measured simultaneously from 100µl plasma by HPLC method according to Catignani [15].

Ferritin concentration, as an indicator of the body's iron pool, was measured from 50µl plasma by a radioimmunassay method, using the reagent kits made by the National Institute of Isotopes.

5.2.2. Statistical analysis

Clinical data on the patients are reported as means \pm standard deviations (x \pm SD). Statistical analyses included both parametric (variance analysis, Tukey test and Student's t test) and nonparametric tests (Wilcoxon rank test). When the variances between pairs of groups differed significantly from each other (p <0.05 in the F-test), we used the Welch test (d probe) instead of a t test to compare the mean values. Correlations between parameters were characterized by calculation of the linear regression and correlation coefficients. The significance level for all tests was taken as p=0.05.

6. RESULTS

6.1. Retrospective study

6.1.1 GSH redox system

A significant increase in the GSSG/GSH as a specific sign of acute, in vivo oxidative stress was only seen in the patients younger than 3 months old with simultaneous active ROP, as compared both with the controls of the same age and the ROP patients of any older age [71-73]. There was a significant negative correlation between the GSH oxidation (measured either as GSSG concentration or as the ratio GSSG/GSH) and

the total Hb concentration in the ROP patients less than 3 months old. Thus, the extent of *in vivo* oxidative stress showed a correlation with the extent of anemia in these prematures with simultaneous active ROP [72].

6.1.2 APH challenge and response: GSH stability test and hemoglobin oxidation

Following an *in vitro* oxidative stress (incubation with APH) compromised antioxidant defense capacity could be detected in all ROP patients. Greater fall in GSH was seen in all the ROP patient groups as compared with the controls. The proportions of oxidized derivatives of Hb (metHb+hemichrome) were higher in each ROP group, as well. There was a highly significant negative correlation between the GSH recycling and the Hb oxidation caused by APH both in the controls and in the patients with ROP. Greater GSH depletion was accompanied by a more extensive oxidation of Hb after a calibrated *in vitro* oxidative stress [71-73].

6.1.3 Blood selenium concentration

Compared to the controls very low blood Se levels were measured in all ROP patient groups reflecting reduced GSH-Px activity in each age group [71,73].

6.2 Prospective study

6.2.1.Individual parameters: gestational age and birth weight

The gestational age and the birth weight of patients diagnosed with stage 1-3 ROP were significantly lower than those of prematures in the other two groups (ROP free and ROP suspects) [70,74-75].

6.2.2. GSH redox system

A significant increase in the GSSG/GSH ratio as a specific sign of acute oxidative stress could be seen in all of our premature patient groups. We did not find significant differences either in concentrations and ratios or in stability of GSH between the patient groups according to their ROP status. A significant negative correlation between the GSH oxidation (measured either as GSSG concentration or as the ratio GSSG/GSH) and the total Hb concentration was detectable in all 3 patient groups [70,74].

6.2.3. Concentrations of free sulfhydryl groups in the prematures and their mothers

Concentrations of plasma -SH groups measured in the ROP patient group were significantly lower than in the other prematures without ROP. By measuring the -SH groups in their mothers' plasma, the same tendency was seen: the lowest -SH group concentrations were detected in the mothers of those prematures suffering from ROP [70,74].

6.2.4. Selenium concentrations in the prematures and their mothers

Extremely low RBC Se levels were detected in the ROP patients compared to the other two premature groups without ROP. Se concentrations in their mothers showed the same relationship: the lowest levels were seen at those mothers whose babies suffered from ROP [70,74].

6.2.5. The effect of vitamin E administration on the concentrations of free sulfhydryl groups and RBC selenium levels

In the ROP-suspect group of prematures vitamin E treatment was started. 30 mg was administered orally, twice a week. The treatment was closely monitored by repeated plasma vitamin E level determinations. At the age of 6 months we could already see the positive effect of vitamin E

on the ophthalmological status, i.e. the avascular, pale periphery began to be vascularised and slow regression was seen. At this time a second biochemical investigation was carried out in our vitamin E treated ROP suspect patients. Both the concentrations of free sulfhydryl groups and Se were increased after per os vitamin E treatment [70,74].

6.2.6. Plasma concentrations of antioxidant vitamins: E and A

There was a marked decrease in plasma vitamin E concentrations in the patient group diagnosed with ROP, as compared both with the other two premature groups and the vitamin E range. However, plasma vitamin E levels in the ROP free premature groups were also slightly below the lowest level of the physiological range, reflecting a general vitamin E deficiency of the preterm neonate.

Maternal vitamin E concentrations showed a very similar tendency: the lowest vitamin E levels were detected in those mothers whose preterm babies suffered from active ROP, concentrations of plasma vitamin E were slightly higher in the other two mother groups. On the other hand, plasma vitamin A concentrations were only lower in our ROP patients, as compared to the other, ROP-free groups and the physiological values. Plasma vitamin A levels of the ROP-free prematures and all of the mothers, regardless of the ophthalmolgical status of their babies, were in the physiological range [75].

6.2.7. Plasma ferritin levels

Plasma ferritin concentration, which is an indicator of the body's iron pool was significantly higher in the ROP patient group, as compared with the other ROP free prematures. Surprisingly, maternal ferritin levels showed the opposite tendency: the lowest plasma ferritin levels were detected in the mothers of the ROP patient group, but ferritin levels in the other two mother groups were still lower than that of their babies [75].

7. DISCUSSION

ROP is a disease of immature retinal vessels, an ocular manifestation of 'Oxygen Radical Disease of prematurity' [106]. The retina is one of the organs most directly exposed to high oxygen tension and the endothelial cells of its microvessels are highly susceptible to free oxygen radical injury. There is evidence that light exposure -even standard levels of nursery light- may also play a role in the pathogenesis of ROP by photosensitization.[30-31]. High levels of a hematogenous photosensitizer, protopophyrin IX, a photoactive compound that produces reactive oxygen species when exposed to light, was detected in preterm neonates as well [13]. The unique sensitivity of the retina to oxidative injury is probably due to its high content of highly unsaturated fatty acids, which are susceptible to the reactive oxygen species generated in the simultaneous presence of light and a high concentration of oxygen. Retinal hemorrhage is a frequent finding in all newborn infants shortly after birth [26]. Prematures, however, are even more prone to develop retinal oxidative injury: besides undergoing a hyperoxic insult on moving from the relatively hypoxic intrauterine environment to room air, they usually require special therapeutic interventions such as administration of high concentrations of oxygen, phototherapy, blood transfusions etc.

The similarity between the human retina and the RBCs concerning their membrane structure (very long chain unsaturated fatty acids with a marked susceptibility to oxidative insult), their metabolism (high demands for glucose and oxygen) and their antioxidant defence mechanisms [22,82] lead us to study the RBC as a model to demonstrate and follow the oxidative status of the RBCs as a biological index of retinal oxidative injury [80,116] in our ROP patients. Furthermore, there is increasing evidence that the efficient glutathione recycling of the RBCs is involved in the protection against oxidative damage not only of the

RBCs themselves, but also of other tissues (e.g. lung) in premature infants [19, 63-65,96].

Based on the fact, that low gestational age and the frequency of blood transfusions are the only parameters independently associated both with the occurrence of ROP and with its severity [20,37,45,89] we hypothetized that, as immaturity and anemia and are common pathological signs of the disease, the RBCs of ROP patients might display a special susceptibility to free oxygen radicals. On the hypothesis of an imbalance between the production of free oxygen radicals and the antioxidant protective capacity of the RBCs, a retrospective study of ROP patients of different ages was carried out first. The aim of our pilot study was to acquire information on the glutathione antioxidant status of the RBCs in ROP patients in different stages of the illness, and to assess the GSH recycling capacity of the RBCs providing the antioxidant protection of intracellular Hb after an in vitro oxidative insult. Intracellular Hb is protected against oxidative injury by the antioxidant mechanisms of the RBCs', mainly by the glutathione redox system. Intracellular GSH plays a key role in the protection of the RBCs not only by protecting Hb from oxidation [124], but also as a scavenger of free hemin [100]. Hemin with its hydrophobic nature, is a more potent catalyst of lipid peroxidation in RBC membrane than nonheme irons, and plays a significant role in the acceleration of RBC destruction [18].

In the control patients of our first, retrospective study, the GSH concentration was highest in the youngest patient group in accordance with the results of previous studies, where the RBCs of healthy newborn babies (both term and preterm) displayed a higher GSH content [19,96] and a more efficient GSSG recycling after an in vitro oxidative insult compared with adults [19].

However, reduced GSH levels together with increased GSSG concentrations, resulting in high GSSG/GSH ratio, were present only in

prematures less than 3 months old simultaneously with the clinical signs of the acute phase of ROP. This finding suggested that the GSSG/GSH was a reliable parameter of an oxidative injury present in the most immature and most susceptible babies with active ROP.

We found a significant negative correlation between the GSH oxidation and the Hb concentration in the prematures with active ROP. This fact supported our hypothesis that the permanent oxidative stress contributed to the development of anemia due to oxidative hemolysis through a GSH-depleting mechanism. The possibility of a defective GSH synthesis as a cause of the reduced GSH concentration in the newborn period has recently been excluded [56].

In another recent study on prematures with chronic lung disease and 31% ROP incidence whose gestational age was similar to that in our group, a significantly reduced GSH concentration was similarly measured in the RBCs on day 28 as compared with the controls [60]. The prolonged oxidative stress, together with the suspected loss of riboflavin, a coenzyme for glutathione reductase, were suggested to result in the impaired GSH recycling [60]. Evidence from previous studies indicated that the GSH recycling capacity was more important in resisting oxygen toxicity than the GSH concentration itself [19,60,108].

A method of calibrated *in vitro* oxidative challenge with APH was evolved by *Beutler* [10] in order to recognize patients with defective G6PD activity resulting in insufficient GSH recycling. Subjects with reduced recycling capacity are in danger of oxidative hemolysis after the administration of oxidant drugs or during infections [5,9,125]. However, in our retrospective study we proved the presence of defective GSH recycling not only in active ROP patients but also in infants and children with preceding ROP as compared with that of the controls. On the basis our findings, we suggest that a defective GSH recycling capacity of RBCs could be a factor predisposing to oxidative hemolysis and ROP.

Glutathione peroxidase (GSH-Px), superoxide dismutase (SOD) and catalase (Cat) are the most important enzymes in the defence system against free oxygen radicals. SOD, of which several different types have been described [58], protects against the superoxide radical and catalyses its transformation from superoxide to hydrogen peroxide. Cat and GSH-Px are necessary for rapid conversion of hyrogen peroxide to molecular oxygen and water. Assessing the operation of the GSH-Px system in vivo, an increased pathway activity has been observed upon exposing isolated perfused rat lung, ox retina and human RBCs to elevated O2 [35]. GSH-Px (E.C. 1.11.1.9) consists of four protein subunits, each of which contains one atom of the element selenium (Se) at its active site. Thus, Se is an integral part of GSH-Px and therefore has a key role in the GSH protection against oxidative damage such as hemoglobin oxidation and the RBC hemolysis [87,90]. Linear relationship has been reported between the RBC's GSH-Px activity and Se concentrations in several studies [83,87]. It has been suggested later by another research group that RBCs of Se deficient individuals not only lack GSH-Px activity but also lack GSH-Px protein, thus Se controls the synthesis of the GSH-Px. [111-112]. This strong association led us to study Se status in order to assess the GSH-Px activity in our patient groups. According to the literature, to determine a long-term index of Se status, the RBC's Se concentration is a more reliable measurement since plasma Se concentration is influenced more readily by changes in the actual Se intake [83]. Therefore we determined the RBC Se concentrations in our retrospective study. The very low blood Se levels measured by us in all ROP patient groups reflected reduced GSH-Px activity in each age group [71,73], as compared to the age matched controls. Surprisingly, Se status of our healthy controls was low as well in comparison to the Western-European normal Se values, which were determined with the same method [115]. This finding suggested that Se depletion in Hungary might be an important predisposing factor to ROP.

In order to further investigate the possible association between low selenium status and development of ROP, a planned, prospective study was warranted, which provides stronger evidence for causation than a retrospective observation. According to our results in the prospective study, extremely low RBC Se levels were detected in the ROP patients compared to the other two premature groups without ROP. Se concentrations in their mothers showed the same relationship: the lowest levels were seen at those mothers whose babies suffered from ROP. The maternal Se deficiency observed may lead to diminished retinal GSH-Px activity in the fetal retina. GSH-Px, the enzyme which provides the only antioxidant protection of human retinal precursor ('spindle') cells before the 28th gestational week, is already detectable in retinas of human embryos weighing more than 160g. [39,41,50,62]. For the proper GSH-Px synthesis and enzymatic activity Se is required. To obtain and maintain an adequate fetal Se level is extremely important because before the 28th gestational week retinal photoreceptors are not secreting the lipid soluble interstitial retinol binding protein (IRBP), a carrier protein for vitamin E, and therefore spindle cells cannot receive any protection from vitamin E supplementation [40, 42-43]. Thus, the younger the infant the more attention should be paid to an adequate supply of water soluble Se, which doesn't require the presence of any carrier protein to protect the spindle cells, in order to create favorable antioxidant retinal environment. According to our results, Se levels in prematures suffering from ROP was particularly low as a result of the diminished maternal supply. The placenta has some barrier function towards Se (3:2) but depending on the maternal level Se does get into the fetal circulation and has positive influence on the fetal antioxidant defence [41].

Several dietary studies have shown that, by world standards, the selenium status of the adult population of Hungary is low [2,11,109]. Close correlation was found between the Se concentration of wheat and human blood [2]. Se concentration of the soil varies widely between geographical areas. The same Hungarian research group reported that the Hungarian rock-soil systems, especially the acid igneous rocks and widely distributed loess and sand formations, where most of the agricultural products are grown, are very low in Se [32]. Our data and results from the relevant literature suggest that Se deficiency as a factor contributing to latent antioxidant deficiency in the Hungarian population plays an important role in the pathogenesis of ROP. Based on this observation, we support the idea that a single dose 'antioxidant cocktail' (Se+vitamin E) given to the high-risk mothers (advanced age, preeclampsia, toxemia, smoking, pregnancy-induced hypertension, etc.) before delivery - as suggested in the literature - might be useful in the prevention of ROP [41]. On the other hand, proper nutrition before and during pregnancy may protect not only the developing fetus from oxidative damage, but also influence the course of pregnancy. In a recent study very low whole blood Se levels and GSH-Px activities were reported in women with miscarriage occurring in the first and second trimesters [126]. In order to improve the Se status of the population Hungarian authors recommend the consumption of bread produced with Se enriched yeast which, according to their results, improve the Se status as soon as within two weeks of supplementation in healthy adults [88]. Another Hungarian group reported the beneficial effect of enteral supplementation of a yeast-selenium on the serum selenium status of premature infants during the first 14 days of life [11].

Apart from the glutathione redox system, free sulfhydryl groups (-SH) in the plasma are significant free radical scavengers. Free -SH groups respond immediately to the oxidative damage, therefore their

concentration reflects the actual antioxidant status of the body. Free -SH groups are mainly provided by the consumption of sulphur-containing aminoacids, such as cystein, methionin, etc. We found that concentrations of free -SH groups were significantly lower in the plasma both of our ROP patients and in their mothers. These findings: -SH depletion and close correlation between the maternal and fetal levels stress again the importance of proper nutrition, especially protein consumption during pregnancy. Based on our data, we suggest, that dietary supplementation with sulphur-containing aminoacids would improve the antioxidant capacity of both the mother and the infant.

Vitamin E is a lipid soluble, chain breaking antioxidant in the plasma. As a scavenger of peroxyl radicals, it is one of the most significant inhibitors of the free radical chain reaction of lipid peroxidation. Low vitamin E status of premature infants was already recognized in 1949 and it was suggested that vitamin E-deficiency might play a role in the etiology of ROP [67]. However, when the role of oxygen was identified in 1953 [14] vitamin E and its possible relation to ROP were forgotten. Support for the vitamin E-deficiency hypothesis came later from ultrastructural investigations [42,51,66]. According to *Hittner*'s observations when retinas of premature infants are exposed to relative hyperoxia, the elevated oxygen tension induces the formation of gap junctions between the adjacent endothelial precursor spindle cells. The appearance of these gap junctions is the first morphologic evidence of oxygen toxicity, resulting in cessation of spindle cell migration and canalisation. The coupling of spindle cells changes these cells from endothelial precursors to sites of synthesis and release of angiogenic factors, which trigger the induction of ROP by neovascularisation from existing vessels [50]. According to this theory, vitamin E supplementation suppresses gap junction formation by

protecting the spindle cells from the oxidative damage, and thus, reduces the severity of ROP [42].

In our study we evaluated the vitamin E status in our patient and mother groups. The marked decrease of plasma vitamin E concentrations reflected vitamin E deficiency both in our ROP patients and in their mothers. However, plasma concentrations of this antioxidant vitamin were always higher in the mothers. According to the literature vitamin E crosses the placenta only in a 4:1 ratio from maternal to infant blood [42,66]. In our study the ratio of maternal and fetal plasma vitamin E concentration was consistent with this placental barrier function. Other studies indicated that maternal and fetal vitamin E storage occurs only late in gestation, mostly towards the end of the third trimester [16,42-43] thus, preterm babies have a higher incidence of vitamin E deficiency compared to term babies. In our mother groups, plasma vitamin E levels were very low, well under the lowest level of the physiological range, reflecting a general vitamin E deficiency already in the mothers. Although there are natural sources of vitamin E (such as vegetable oils, nuts, grains, green leafy vegetables...etc) we recommend that vitamin E supplementation during pregnancy should be considered in Hungary.

On the other hand, there is still a controversy regarding vitamin E supplementation in preterm infants [17,40,43,46,77-78]. Numerous clinical trials were performed to test the efficacy and safety of vitamin E in suppressing the development of ROP [17,40,43,46,77-78]. This controversy on vitamin E treatment is partly due to the differences in experimental design, the dose of vitamin E and the route of administration applied in the different studies. The initial, rapid intravenous administration resulted in high plasma peak levels (5mg/dl), causing an increased incidence of life threatening side-effects, such as retinal and haemorrhages [17,78],sepsis necrotising intraventricular and enterocolitis. [46,91]. A slower rise in plasma vitamin E concentration could be achieved by intramuscular administration, but local tissue necrosis and secondary calcification may follow. [93]. According to Hittner's observation -based on animal studies- the oral route of administration, which results in slower rise in plasma concentration, is optimal for retinal vitamin E uptake [40-41]. According to the recommendation of the American Academy of Pediatrics, the optimal plasma level of vitamin E in preterm infants is 0.5-2.0mg/dl [3]. Vitamin E supplementation should be initiated in the first hours of life and continued until retinal vascularistion is completed as determined by an indirect ophthalmoscopic examination. Further support for oral vitamin E supplementation comes from a study involving post-mortem measurement of vitamin E levels in human, premature retinas [66]. Baseline vitamin E levels were found to be extremely low. When compared retinal vitamin E levels in vitamin E supplemented and unsupplemented infants, a significant difference in retinal vitamin E levels was found, but only in infants older than 28 weeks gestational age. This finding suggests an insufficient retinal in uptake of vitamin E in the smallest and illest infants as a result of the insufficient amounts of IRBP in the subretinal space [40,42-43]. Thus, vitamin E provides incomplete, age dependent antioxidant protection, which shifted our focus to the already endogenous Se dependent GSH-Px and the beneficial, non-age dependent effect of Se supplementation. There is, however, a synergism between Se and vitamin E: to a considerable extent, the effects of Se deficiency can be overcome by giving excess doses of vitamin E and vice versa [35]. This synergism provides an explanation to our results in the ROP suspect group: both the ophthalmological and Se status improved after per os vitamin E treatment.

Vitamin A, like vitamin E, is an important inhibitor of the free radical chain reaction of lipid peroxidation. *In vitro* studies have shown that various forms of vitamin A can exert antioxidant effects that are more potent than those provided by vitamin E [94]. Adequate vitamin A intake

is essential for successful pregnancy outcome, since normal embryonic development, both cell growth and differentiation depend on the proper maternal supply. In our study, maternal vitamin A levels were in the normal physiological range, reflecting no vitamin A deficiency. There is a controversy in the literature regarding vitamin A supplementation during pregnancy. According to the most recent study on nutrition, one of the four most important forms of malnutrition worldwide is vitamin A deficiency [104]. Subclinical vitamin A deficiency is affects at least 251 million people, including pregnant women. Several clinical trials have shown that supervised vitamin A supplementation in these cases had positive effects on the outcome of pregnancy [4]. Beneficial effects of vitamin A supplementation on pregnancy- induced hypertension have been reported as well [69].

Another research group raised the issue of the effect of maternal smoking on the plasma levels of vitamin A and E: significantly lower levels of vitamin A and E were measured in the placentas of those mothers, who smoked during pregnancy. They suggest supervised antioxidant vitamin supplementation in order to protect newborns from the potentially harmful effect of maternal smoking [52].

On the other hand, excessive dietary intake of vitamin A (e.g. multivitamins) has been associated with teratogenicity in humans, although less than 20 cases were reported over 30 years [4]. There are also several retinoids (vitamin A derivates) that are effective drugs for therapy of skin diseases and some types of cancer, but the application of this class of compounds is forbidden during pregnancy due to their teratogenic activity. Fetal malformations including craniofacial, cardiac, thymic and central nervous system abnormalities were observed as a sequel of isotreninoin treatment (prescribed for severe cystic acne) during pregnancy. [54,119].

An animal study, which was performed to provide risk assessment to obtain information safe dosage of vitamin A during human pregnancy recommends a dose range of approximately 25000 to 37000 IU/day [36]. Nutritional studies suggest that increasing the amount of Ω3 fatty acid in the diet alone, by eating oil-rich fish either fresh or canned as often as twice or three times a week provides optimal protein, vitamin A and D supply during pregnancy [88]. The most recent guideline for vitamin A supplementation during pregnancy suggests that initiation of vitamin A therapy should be carefully examined in each case according to the risk-benefit ratio. The final decision should take into account the estimated vitamin A status of the woman, the availability of vitamin A-rich foods in her diet, and whether her supplementation can be supervised [4].

On the other hand, in spite of the physiological plasma concentrations measured in our mother groups, vitamin A status of our ROP patients was low. Our result was similar to the observation of other authors [21,61,94,118]. They suggest that premature infants have subnormal or low serum retinol concentrations, which have been associated with increased risk of developing chronic lung disease and sepsis. Randomized, controlled trials were undertaken to asses whether vitamin A supplementation beyond that routinely given can reduce the incidence of chronic lung disease [21]. According to their results, supplementing very low birth weight infants with vitamin A is associated with reduction in oxygen requirement among survivors at 36 weeks postconceptional age. Two studies reported even a reduced incidence of ROP in vitamin A supplemented infants [21]. However, in the most recent systematic review article on vitamin A supplementation Darlow suggests that further clinical studies should assess the benefits, safety and acceptability, the optimal dose and route of administration of vitamin A to the high-risk preterm infants [21].

Iron is essential in the human body for the synthesis of a huge range of enzymes and other proteins involved in respiration, oxygen (O₂) transport and several redox reactions. Yet iron is potentially dangerous by having the ability to undergo quick valence changes, which enables this metal to be a powerful catalyst in the production of reactive oxygen species by facilitating the formation of the highly reactive hydroxyl radical (OH⁻) from superoxide (O₂⁻). [35]. Sullivan [106] proposed that iron plays an important role in the pathogenesis of the 'Oxygen Radical Disease of Prematurity'. According to his hypothesis, premature infants are abnormally susceptible to oxygen radical injury because of developmentally low levels of the iron-associated antioxidant proteins (such as the iron-oxidizing ceruloplasmin and iron-binding transferrin) combined with postnatal changes of iron-metabolism.

Birth is a point of transition to the higher oxygen concentration of the extrauterine environment, which is associated with virtual cessation of red blood cell formation. This adjustment has major effect on the neonatal iron metabolism since red blood cell lysis continues or — in cases of hemolysis — increases. Thus, there is an increase in the amount of iron that must be stored, especially in those prematures who require whole blood transfusions or iron supplementation. As a consequence of the developmentally low transferrin concentrations in premature infants, very high transferrin saturations (100%) develop in a very short time. Thus, the plasmas of prematures have no more iron-binding capacity, leading to the appearance of 'free' iron. The presence of this potentially harmful, bleomycin-detectable free iron in the plasma of premature infants has been first reported by *Evans* [25]. Free iron enhances the risk of oxidative injury, especially in premature infants who have greater susceptibility due to their less effective antioxidant systems.

Most intracellular iron is stored in ferritin, which consists of a protein shell and an iron core that can hold up to 4500 ions of iron per

molecule. Iron deposited in ferritin is in an insoluble oxidized from, providing a harmless iron pool for the human body. Plasma ferritin is considered the best measure of total body iron [35]. We therefore measured plasma ferritin concentrations in order to investigate the association between the mother's and preterm infant's iron status. According to our results, marked decrease in plasma ferritin concentration was detectable in all mothers, reflecting iron deficiency in all groups of mothers. The lowest maternal ferritin concentrations, however, were measured in mothers of ROP patients.

In the literature, recent concerns have been voiced about harmful effects of iron supplementation during pregnancy. Questions were raised about the efficacy of iron supplementation, about the side effects of iron treatment, including its potential for oxidation of lipids and DNA [55,92]. It is suggested that the rationale of routine iron supplementation during pregnancy needs to be re-examined [55].

High plasma ferritin concentrations were observed, however, in our ROP patients, reflecting an iron overload in this group. Similar volumes of plasma ferritin levels were observed by *Sullivan*, by detecting ferritin levels in prematures that were more than 10 times the upper limit of normal for adults [107]. In our study, in spite of the mothers' obvious iron deficiency, there was a marked iron overload in the premature infants. In spite of having high plasma ferritin values, these premature infants usually suffer from early anaemia. Thus, they require special therapeutic interventions such as blood transfusions, iron supplementation, etc. The level of free iron immediately before and after blood transfusion in the plasma of preterm infants, suffering from ROP and/or chronic lung disease has been investigated recently [38]. According to the results of this study, plasma levels of free iron were significantly increased after blood transfusion. This finding was specific to preterm infants and was not observed in full term infants after blood transfusion. This finding

suggests that the available iron overloads the premature infant's developmentally limited iron-handling capacity, leading to the oxygen radical disease of prematurity. Several studies were carried out to find a relationship between 'iron-associated risk factors' (e.g. red blood cell transfusion protocol) and the predominant site of the oxygen radical injury (retinal, lung, etc) [24,37,45]. Logistic regression analysis has demonstrated that apart from the gestational age, the frequency of blood transfusions is the only parameter independently associated both with the occurrence of ROP and with its severity [20, 37, 45, 89]. Another prospective, observational study found close correlation between the iron status and the volume of transfused blood and an increased risk for ROP [45].

A recent, retrospective study examined the role of anaemia in the development of ROP. According to their results, infants who remained severely anemic for longer periods of time developed milder ROP, than less anaemic infants who obviously received more transfusions [24]. Thus, iron deficiency may also be protective in certain types of oxygen radical mediated injuries.

In order to prevent iron overload by reducing the need for blood transfusions during the chronic anemia of prematurity, several studies were carried out to assess the efficacy of recombinant human erythropoeitin (EPO) [59,97]. Administration of EPO mobilizes iron from the plasma, decreases iron-saturation of transferrin, increases the number of reticulocytes and increases erythropoiesis. These studies are equivocal in suggesting the administration of recombinant human EPO; at a weekly dose of 600 U/kg because it moderates the course of chronic anemia, appears safe and leads in most cases to the reduction of transfusion requirement in preterm infants. Based on the fact that the frequency of blood transfusions is independently associated both with the occurrence of ROP and with its severity [20, 37, 45, 89], we propose that the

administration of EPO, by reducing the need for transfusions might be useful in the prevention of ROP.

8. CONCLUSION

The aim of our work was to investigate the role of oxidative stress in the pathogenesis of ROP. In order to detect the presence of oxidative stress and find biochemical markers in ROP patients, which explain their special susceptibility to oxidative injury, retrospective and prospective studies were carried out. Our results led us to the following conclusions.

- 1. The RBC's GSSG/GSH ratio is an adequate parameter to indicate the *in vivo* oxidative stress in the acute phase of ROP. The signs of an acute oxidative stress could only be seen in the 3-months-old or younger patients, supporting Saugstad's hypothesis [90] that ROP is a part (as the retinal manifestation) of the 'Oxygen Radical Disease of Prematurity'.
- 2. In response an *in vitro* oxidative stress compromised antioxidant defense capacity could be detected in all ROP patients even later in childhood suggesting that ROP probably may develops in those premature infants who have reduced antioxidant defense capacity (either genetic or acquired).
- 3. Selenium is not only an integral part of GSH-Px enzyme, but also acts as an antioxidant itself by playing a role in the regeneration of vitamin E. The very low selenium levels measured in all our ROP patients both in our retrospective and prospective studies suggest that selenium

depletion in Hungary might play an important role in the pathogenesis of ROP.

- 4. The fact that during our screening for ROP in our prospective study we could only diagnose 5 cases of mild ROP among 60 high-risk premature infants, leads us to the conclusion that the management of preterm infants at the Perinatal Intensive Care Unit of our University and the secondary treatment at Children's Hospital is very careful.
- 5. We found that gestational ages and the birth weights of patients diagnosed with ROP were significantly lower, which confirms the importance of immaturity as one of the most significant risk factors for ROP.
- 6. The close correlation found between the low serum levels of -SH and Se of mothers and babies suggest that dietary supplementation with sulfur containing aminoacids (e.g.methionin, cystein) and Se during pregnancy would improve the antioxidant capacity of premature infants.
- 7. Considering the fact that marked decrease of plasma vitamin E concentrations were determined both in our ROP patients and in their mothers, we can conclude that an 'antioxidant cocktail' suggested in literature (containing Se and vitamin E) given to the high-risk mothers (advanced age, smoking, toxemia, pregnancy-induced hypertension, etc.) before delivery might be useful in prevention of ROP.
- 8. According to our results, *per os* vitamin E supplementation seems to have a positive effect on preventing the progression of ROP. Because

of the potential harmful side effects, however, vitamin E administration must be closely monitored by repeated measurements of plasma vitamin E levels.

9. The fact, that in spite of iron deficiency in their mothers, fully saturated iron pools were detectable in the preterm infants, leads us to the conclusion that during the first 6 weeks of life iron overload might be one of the main factors leading to ROP. Therefore we suggest that in the clinical management of premature infants all interventions that may result in excessive iron load (transfusions, iron supplementation, etc.) may contribute to the development of ROP. We propose that the administration of EPO as a treatment option for chronic anemia might be useful in the prevention of ROP by reducing the need for transfusions.

9. MESSAGE

Although the proportion of premature infants who become blind of ROP has decreased, the number of children with visual disability is still high. As an ophthalmologist I have seen retinas getting detached despite the appropriate treatment resulting blindness and phthisis (disfiguring shrinkage) of the affected eye. Even effective and appropriate ophthalmological interventions have side effects: decreased peripheral vision from cryotherapy, transient or permanent cataracts from vitreoretinal surgery, etc. Fortunately, ROP has a tendency for spontaneous regression, but even in these cases infants are predisposed to amblyopia, strabismus and other disorders requiring long-lasting ophthalmological treatment. For this reason, the only solution for retinopathy of prematurity would be prevention. In order to be able to

prevent this disabling neovascular retinopathy we have to be determined in the continuing search for possibly preventable environmental and individual factors leading to ROP. According the *Lancet Editorial*: 'The focus of preventive attention should probably shift away from neonatology towards obstetrics and public health, since it is only by developing effective methods of avoiding premature delivery and extreme low birthweight that we are likely to bring the unexpectedly longrunning saga of ROP to a close '[84].

10. ACKNOWLEDGEMENTS

This work was supported financially by the Hungarian Research Fund (OTKA F20262; T22562), and the Hungarian Ministry of Welfare (ETT 625/13; 631/08) research grants.

I am greatly indebted to Professor Lajos Kolozsvari for his encouragement and support. He provided me an excellent opportunity and challenge to work as the head of the Pediatric Ophthalmology Unit. This environment inspired and motivated me to do further research on this complex topic.

I acknowledge to Professor Sandor Pinter for inviting me to join the Ph.D. program of his department. I am grateful both to him and Professor Sandor Turi for giving me the opportunity to conduct the biochemical part of my study in the Research Laboratory of the Department of Pediatrics.

I am extremely thankful to Professor Ildiko Suveges from whom I learned the foundation of ophthalmology. She was always a very motivating teacher and directed my interest towards pediatric ophthalmology.

I wish to thank to Professor Helga Hammer who was always very supportive and helpful to me.

I am very grateful to Dr. Zsuzsanna Pelle whose enthusiasm and dedication directed me to pediatric ophthalmology. Her knowledge, her love and patience towards children provided a positive example for me. She taught me how to examine the eye of the delicate prematures, how to

approach a protesting child, and how to deal with parents and grandparents.

I acknowledge Dr. Agnes Szabo for her patient-oriented professionalism and for providing ultrasound measurements to establish precise diagnoses.

I am indebted to Perinatal Intensive Care Unit led by Dr Marta Katona, where they provided extremely careful oxygen monitoring and intensive management. They were excellent partners throughout of our studies.

I would like to thank all my colleagues and pediatric nurses, especially Beatrice Varadi and Balintne Jutka, for their help and support.

I am especially thankful to my mother and mentor Dr. Ilona Nemeth who was tirelessly supportive over the past few years. She taught me how to conduct research and how to write scientific articles. She was always available when I needed her advice.

My father Professor Gyula Papp set the highest standards of scientific curiosity and enthusiasm. His boundless energy, strict work ethics and goal-oriented determination always inspired me.

I also thank my sister Eszter for reviewing the first draft of my thesis.

Without my husband Sandor's support and motivation I would not have been able to face all the challenges I had to. I am especially thankful to him.

11. REFERENCES

- [1] Akerboom, T.P.M., Sies, H. Assay of glutathione, glutathione disulphide and glutathione mixed disulphides in biological samples.

 Methods Enzymol 77:373, 1981.
- [2] Alftan, G., Bogye, G., Aro, A., Feher, J. The human selenium status in Hungary. J *Trace Elem Electrolytes Health Dis* 6: 233, 1992.
- [3] American Academy of Pediatrics Committee on Nutrition. *Pediatrics* in Review 14:128, 1993.
- [4] Azais-Baesco, V., Pascal, G. Vitamin A in pregnancy: requirements and safety limits. *Am J Clin Nutr* 71: 1325, 2000.
- [5] Baechner, R. L., Nathan, D. G., Castle, W. B. Oxidant injury of caucasian glucose-6-phosphate dehydrogenase deficient red blood cells by phagocytosing leukocytes during infection. *J Clin Invest* 50:2466, 1971.
- [6] Bard, H., Cornet, A., Orquin, J., Doray, B. H. Retrolental fibroplasia and exchange transfusions. *Pediatr Res* 9: 362, 1975.
- [7] Becker, H., Lieser, K., Heller, K. Einfluss und Zusammenhang verschiedener Risikofaktoren bei der Entstehung der Retinopathia praematurorum. Klin Mbl Augenheilk 196: 456, 1990.
- [8] Ben-Sira, I., Nissenkorn, I., Kremer, I. Retinopathy of prematurity. Surv Ophthalmol 33: 1, 1988.
- [9] Beutler, E. Genetic disorders of red cell metabolism. *Med Clin North America* 53:813, 1969.
- [10] Beutler, E. The glutathione instability of drug-sensitive red cells. A new method for the in vitro detection of drug sensitivity. *J Lab Clin Med* 49:84, 1957.
- [11] Bogye, G., Alftan, G., Machay, T. Randomized clinical trial of enteral yeast-selenium supplementation in preterm infants. *Biofactors* 8:139, 1998.

- [12] Bossi, E., Koerner, F., Flury, B., Zulauf, M. Retinopathy of prematurity: a risk factor analysis with univariante and multivariante statistics. *Helv Paediatr Acta* 33: 307, 1984.
- [13] Bynoe, L.A., Gottsch, J.D., Sadda, S.R., Panton, R.W., Haller, E.M., Gleason, G.A. An elevated hematogenous photosensitizer in the preterm neonate. *Invest Ophthalmol Vis Sci* 34:2878, 1993.
- [14] Campell, K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia: a clinical approach. *Med J Aust* 2: 48, 1950.
- [15] Catignani, G.L, Bieri, J.G. Simutaneous determination of retinol and alpha-tocopherol in serum or plasma by lipidchromatography. *Clin Chem* 29: 708, 1983.
- [16] Chan, D.K., Lim, M.S., Choo, S.H., Tan, I.K. Vitamin E status of infants at birth. *J Perinat Med* 27: 395, 1999.
- [17] Chiswick, M.L., Wynn, J., Toner, N. Vitamin E and intraventricular haemorrhage in the newborn. *Ann NY Acad Sci* 393:109,1982.
- [18] Chiu, D. T-Y., van den Berg, J. J. M., Kuypers, F. A., Hung, I-J., Wei, J-Sh., Liu, T-Z. Correlation of membrane lipid peroxidation with oxidation of hemoglobin variants: possibly related to the rates of hemin release. *Free Rad Biol Med* 21:89, 1996.
- [19] Clahsen, P. C., Moison, R.M.W., Holtzer, C.A.J., Berger, H. M. Recycling of glutathione during oxidative stress in erythrocytes of the newborn. *Ped Res* 32:399, 1992.
- [20] Cooke, R.W.I., Clark, D., Hickey-Dwyer, M., Weindling A.M. The apparent role of blood transfusions in the development of retinopathy of prematurity. *European Journal of Pediatrics* **152:833**, 1993.
- [21] Darlow, B.A., Graham, P.J. vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants (Cochrane Review) In: *The Cochrane Library* 3, 2001.

- [22] De La Paz, M. A., Zhang, J., Fridovich, I. Antioxidant enzymes of the human retina: effect of age on enzyme activity of macula and periphery. *Curr Eye Res* 15:273, 1996.
- [23] Drack, A. V. Preventing blindness in premature infants. Editorial.

 The New England Journal of Medicine 338:1620, 1998.
- [24] Englert, J.A., Saunders, R.A., Purohit, D., Hulsey, T.C., Ebeling, M. The effect of anaemia on retinopathy of prematutity in extremely low birth weight infants. *J Perinatol* 21:21, 2001.
- [25] Evans, P.J., Evans, R., Kovar, I.Z., Holton, A.F., Halliwell, B. Bleomycin-detectable iron in the plasma of premature and full-term neonates. *FEBS Letters* **303**:210, 1992.
- [26] Flynn, J. T.; Tasman, W., eds. Retinopathy of Prematurity. A Clinician's Guide New York: Springer-Verlag. 1992.
- [27] Foos, R.Y. Acute retrolental fibroplasia. Albrecht Von Graefes Arch Klin Exp Ophthalmol 195:87, 1975.
- [28] Gerschman, R., Gilbert, D.L., Nye S.W., Fenn, W.O. Role of anti-oxidants and glutathione in oxygen-poisoning. *Fed Proc* 14:56, 1955.
- [29] Gibson, D. L., Sheps, S. B., Uh, S. H., Schechter, M. T., McCormick, A. Q. Retinopathy of prematurity-induced blindness: birth-specific survival and the new epidemic. *Pediatrics* 21:241, 1995.
- [30] Glass, P. Light and the developing retina *Doc Ophthalmol* 74:195, 1990.
- [31] Glass, P., Avery, G.B., Subramanian, K.N., Keys, M.P., Sostek, A.M. Effect of bright light in the hospital nursery on the incidence of retinopathy of prematurity. *New England Journal of Medicine* 313:401, 1985.
- [32] Gondi, F., Panto G., Feher, J., Bogye, G., Alfthan, G. Selenium in Hungary. The rock-soil-human system. *Biol Trace Elem Res* 5: 299, 1992.

- [33] Gunn, T.R.; Easdown, J. Outerbridge, E.W.; Aranda, J.W. Risk factors in retrolental fibroplasia *Pediatrics* 65: 1096, 1980.
- [34] Güntherberg, H., Rapaport, S. Eine Methode zur Bestimmung des oxydierten Glutathions. *Acta Biol Med Germ* 20:559, 1968.
- [35] Halliwell, B, Gutteridge, J.M. C. Free radicals in biology and medicine. University Press, Oxford, 1999.
- [36] Hendrickx, A.G., Peterson, P., Hartmann, D., Hummler, H. Vitamin A teratogenicity and risk assessment in the macaque retinoid model. Reprod Toxicol 14:311, 2000.
- [37] Hesse, L., Eberl, W., Schlaud, M., Poets, C. F. Blood transfusion. Iron load and retinopathy of prematurity. *Eur J Pediatr* **156:**465, 1997.
- [38] Hirano, K., Morinobu, T., Hirai, M., Ran, R., Ogawa, S., Tamai, H, Ogiara, T. Blood transfusion increases radical promoting non-transferrin bound iron in preterm infants. *Arch Dis Child Fetal Neonatal Ed* 84:F188, 2001.
- [39] Hittner, H. M., Kretzer, F. L., Lane H. W. Selenium dependent glutathione peroxidase in preterm human retinas. *Fed Proc* **46**:566, 1987.
- [40] Hittner, H. M., Kretzer, F.L.: Retrolental fibroplasia and vitamin E in preterm infant: comparison of oral versus intramuscular: oral administration. *Pediatrics* 73:283, 1984.
- [41] Hittner, H. M., Kretzer, F.L.: Retinopathy of Prematurity, Current Concepts and Controversies Decker Inc., Toronto, 1986.
- [42] Hittner, H.M., Godio, L.B., Speer, M.E., Rudolph, A.J., Taylor, M.M., Blifeld, C., Kretzer, F.L. Retrolental fibroplasia: Further clinical evidence and ultrastructural support for efficacy of vitamin E in preterm infant. *Pediatrics* 71:423, 1983.
- [43] Hittner, H.M., Godio, L.B., Rudolph, A.J., Adams, J.M., Garcia-Prats, J.A., Friedman, Z., Kautz, J.A., Monaco, W.A. Retrolental

- fibroplasia: efficacy of vitamin E in a double blind clinical study in preterm infants. *N Engl J Medicine* **305**:1365, 1981.
- [44] Imre, G. Studies on mechanism of retinal neovascularisation: Role of lactic acid. *Br J Ophthalmol* 48:75, 1964.
- [45] Inder, T. E., Clemett, R. S., Austin, N. C., Graham, P., Darlow, B. A. High iron status in very low birth weight infants is associated with an increased risk of retinopathy of prematurity. *J Pediatr* 131:541, 1997.
- [46] Johnson, L., Quinn, G.E., Abbasi, S., Goldstein, D., Sacks, L., Porat, R., Fong, E., Delivora-Papdopoulos, M., Pecham, G. Effect of sustained pharmacologic vitamin E levels on incidence and severity of retinopathy of prematurity: A controlled clinical trial. *J Pediatr* 114: 827, 1989.
- [47] Johnson, L., Schafer, D.B., Blesa, M.I., Boggs, T.R. Factors predisposing to RLF-complications of pregnacy. *Pediatr Res* 12:527, 1978.
- [48] Kalina R.E., Hodson W.A., Morgan, B.C. Retrolental fibroplasia in a cyanotic infant. *Pediatrics* **50**:765, 1972.
- [49] Koster, J.F., Biemond, P., Swaak, A.J.G. Intracellular and extracellular sulphydryl levels in rheumathoid arthritis. *Ann Rheum Dis* 45: 44, 1986.
- [50] Kretzer, F. L., Hittner, H. M. Retinopathy of prematurity: clinical implications of retinal development. *Arch Dis Childhood* **63**:1151, 1988.
- [51] Kretzer, F. L., Mehta, R.S., Johson, A.T., Hunter, D.G., Brown, E.S., Hittner, H.M. Vitamin E protects against retinopathy of prematurity through action on spindle cells. *Nature* 309: 793, 1984.
- [52] Lakowska-Kita, T., Szymborski, J., Chelchowska, M., Czerwinsk, B., Kucharski, K. Levels of lipid peroxides and of some antioxidants in placenta and cord blood of newborns whose mother smoked during pregnancy. *Med Wieku Rozwoj* 5:35, 2001.

- [53] Lalonde, L., Jean, Y., Roberts K.D., Chapdelaine A., Bleau, G. Fluorometry of selenium in serum or urine. *Clin Chem* 28: 172, 1982.
- [54] Lammer, E.J., Chen, D.T., Hoar, R.M., Agnish, N.D., Benke, P.J., Braun, J.T., Curry, C.J., Fernhoff, P.M., Grix, A.W., Lott, I.T. Retinoic acid embryopathy N Engl J Med 313:837, 1985.
- [55] Lao, T.T., Tam, K.F., Chan, L.Y.Third trimester iron status and pregnancy outcome in non-anaenic women; pregancy unfavourably affected by maternal iron excess. *Hum Reprod* **15**:1843, 2000.
- [56] Lavoie, J-C., Chessex, P. Development of glutathione synthesis and γ-glutamyltranspeptidase activities in tissues from newborn infants. Free Rad Biol Med 24:994, 1998.
- [57] Lucey, J. L., Dagman, B. A re-examination of the role of oxygen in retrolental fibroplasia. Pediatrics 73:82, 1984.
- [58] Marklund, S.L. Clinical aspects of superoxide dismutase. *Med Biol* **62**:130, 1984.
- [59] Meyer, M.P., Meyer, J.H., Commerford, A., Hann, F.M., Sive, A.A. Moller, G., Jacobs, P., Malan, A.F. Recombinant human erythropoietin the treatment of the anaemia of prematurity: results of a double blind, placebo controlled study. *Pediatrics* 93:918, 1994.
- [60] Moison, R.M.W., Haasnoot, A. A., Van Zoeren-Grobben, D., Berger, H. M. Red blood cell glutathione and plasma sulfhydryls in chronic lung disease of the newborn. *Acta Paediatr* 86:1363, 1997.
- [61] Mupanemuda, R.H., Lee, D.S., Fraher, L.J., Koura, I.R., Chance, G.W. Postnatal changes in serum retinol status in very low birth weight infants. *Early Hum Dev* 38:45, 1994.
- [62] Naash, M. I., Nielsen, J. C., Anderson, R.E. Regional distribution of glutathione peroxidase and glutathione-S-transferase in adult and premature human retinas. *Invest Ophthalmol Vis Sci.* 29:149, 1988.
- [63] Nemeth I., Boda D.: Oxidized and reduced glutathione levels in blood samples from premature infants with RDS and critically ill

- children. In: Oxygen Free Radicals and Tissue Injury. Eds: Matkovics, B., Boda, D., Kalasz, H., Akademiai Kiado, Budapest p269, 1988.
- [64] Nemeth I., Boda D.: The ratio of oxidized/reduced glutathione as an index of oxidative stress in various experimental models of shock syndrome. *Biomed Biochim Acta* 48: 53, 1989.
- [65] Nemeth, I, Boda, D. Blood glutathione redox ratio as a parameter of oxidative stress in premature infants with IRDS. *Free Rad Biol Med* 16:347, 1994.
- [66] Nielsen, J. C., Naash, M. I., Anderson, R.E. The regional distribution of vitamins E and C in mature and premature human retinas. *Invest Ophthalmol Vis Sci* 29:22, 1988.
- [67] Owens W.C., Owens, E.U. Retrolental fibroplasia in premature infants: II.Studies on the profilaxis of the disease: The use of alphatocopheryl acetat. *Am J Ophthalmol* 32:1631, 1955.
- [68] Oxygen restriction and retinopathy of prematurity. Editorial. *Lancet* 339: 961, 1992.
- [69] Pandey, S., Srivastava, R., Mukerjee, D., Khattri, S., Shanker, K. Effect of vitamin A on free radical cascade in pregnancy induced hypertension. *Boll Chim Farm* 139:98, 2000.
- [70] Papp, A., Nemeth I. Pelle S., Tekulits, P. A prospective, biochemical study on the antioxidant defense capacity of patients suffering from Retinopathy of Prematurity. *Orv Hetil* **201**: 201, 1997.
- [71] Papp, A., Nemeth, I. and Pelle, Zs. A retrospective, biochemical study on the antioxidant defense capacity of patients suffering from Retinopathy of Prematurity. *Orv Hetil* **134**: 1021, 1993.
- [72] Papp, A., Nemeth, I., Karg, E, Papp, E. Glutathione status in retinopathy of prematurity. Free Rad Biol Med 27: 738, 1999.
- [73] Papp, A., Nemeth, I., Pelle, Zs. A retrospective ophthalmological and biochemical study on the antioxidant defense capacity of patients

- suffering from retinopathy of prematurity. In: Mozsik Gy., Emerit I., Feher J., Matkovics B., Vincze A. (Eds.): Oxygen Free Radicals and Scavengers in the Natural Sciences, Akademiai Kiado, Budapest, pp.203, 1993.
- [74] Papp, A., Nemeth, I., Pelle, Zs., Tekulics, P. A one-year ophthalmical and biochemical follow-up study on prematures with high risk of retinopathy. In: Mozsik Gy., Emerit I., Feher J., Matkovics B., Vincze A. (Eds.): Oxygen Free Radicals and Scavengers in the Natural Sciences, Akademiai Kiado, Budapest, pp. 199, 1993.
- [75] Papp, A., Nemeth, I., Pelle, Zs., Tekulics, P. Antioxidant vitamins and iron-pool in preterm infants suffering from Retinopathy of Prematurity. *Opht Hung (Szemeszet)* 132:51, 1995.
- [76] Phelps, D. L. Retinopathy of prematurity. Current Problems in Pediatrics 22:349, 1992.
- [77] Phelps, D.L. Vitamin E and retrolental fibroplasia in 1982. *Pediatrics* 70:420, 1982.
- [78] Phelps, D.L., Rosenbaum, A., Isenberg, S.J., Leake R.D., Dorey, F. Effect of IV tocopherol (vitamin E) on retinopathy of prematurity. *Pediatr Res* 19:357A, 1985.
- [79] Phelps, D.L. Retinopathy of prematurity: An estimate of vision loss in the United States-1979. *Pediatrics* 67:924, 1981.
- [80] Prashar, S., Pandav, S. S., Gupta, A., Nath, R. Antioxidant enzymes in RBCs as a biological index of age related macular degeneration. Acta Ophthalmol 71:214, 1993.
- [81] Prendiville, A., Schulenburg, W. E. Clinical factors associated with retinopathy of prematurity. *Arch Dis Child* **63**:522, 1988.
- [82] Puertas, F. J., Diaz-Llopis, M., Chipont, E., Romá, J., Raya, A., Romero, F. J. Glutathione system of human retina: Enzymatic conjugation of lipid peroxidation products. *Free Rad Biol Med* 14:549, 1993.

- [83] Rea, H. M. Relation between erythrocyte selenium concentrations and glutathione peroxidase activities of New Zealand residents and visitors to New Zealand. *Br J Nutr* 42: 201, 1979.
- [84] Retinopathy of prematurity. Editorial. Lancet 337:83, 1991.
- [85] Rice, R. Fish and healthy pregancy: more than just a red herring! Prof Care Mother Child 6:171, 1996.
- [86] Rogers, S, Witz, G; Anwar, M.; Hiatt, M, Hegyi, T. Antioxidant capacity and oxygen radical diseases in the preterm newborn. *Arch Pediatr Adolescent Med* 154:544, 2000.
- [87] Rotruck, J. T. Selenium: biochemical role as a component of glutathione peroxidase. *Science* 179: 588, 1973.
- [88] Rumi, G., Imre L, Sulle, C., Lassune, M.Z., Sarudi, I., Kelemen, J. Selenium supplementation with bread. *Orv Hetil* 135:2371, 1994.
- [89] Sacks, L. M., Schaffer, D. B., Anday, E. K., Peckham, G. J., Delivoria-Papadopoulos, M. Retrolental fibroplasia and blood transfusion in very low-birth-weight infants. *Pediatrics* **68:**770, 1981.
- [90] Saugstad, O.D. Oxygen toxicity in the neonatal period. *Acta Paed Scand* 79:881, 1990.
- [91] Schaffer, D.B., Quinn, G.E., Johnson, L., Weston, M., Herrmann, N., Bowen, F.J. Vitamin E and retinopathy of prematurity: follow up at one year. *Ophthalmology* 92:1005, 1985.
- [92] Scholl, T.O., Reilly, T. Anaemia, iron and pregnancy outcome. *J Nutr* 130:443S, 2000.
- [93] Schroeder, H., Schulz, M., Aeissen, K. Muscular calcification following injection of vitamin E in newborn infants. *Eur J Pediatr* **142**: 145, 1984.
- [94] Schwarz, K.B., Cox, J.M., Sharma, S., Clement, L., Humphrey, j., Gleason, c., Abbey, H., Sehnert, S.S., Risby, T.H. Possible antioxidant effect of vitamin A supplementation in premature infants. J Pediatr Gastroenterol Nutr 25:408, 1997.

- [95] Seibert, V, Lindenkamp, O. Risk factors in retinopathy of prematurity. A multivariate statistical analysis. *Ophthalmologica* **214**: 131, 2000.
- [96] Shahal, Y., Bauminger, E. R., Zmora, E., Katz, M., Mazor, D., Horn, S., Meyerstein, N. Oxidative stress in newborn erythrocytes. *Ped. Res.* 29:119, 1991.
- [97] Shannon, K.M., Keith, J.F., Mentzer, W.C., Ehrenkranz, R.A., Brown, M.S., Widness, J.A., Gleason, C.A., Bifano, E.M., Millard, D.D., Davis, C.B. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. *Pediatrics* 95:9, 1995.
- [98] Shastry, B. S., Pendergrast, S. D., Hatzer, M. K., Liu, X., Trese, M. T. Identification of missens mutations in the Norrie disease gene associated with advanced retinopathy of prematurity. Arch. Ophthalmol. 115:651, 1997.
- [99] Shohat, M., et al. Retinopathy of prematurity: incidence and risk factors. *Pediatrics* 72: 159, 1983.
- [100] Shviro, Y., Shaklai, N. Glutathione as a scavenger of free hemin. A mechanism of preventing red cell membrane damage. *Biochem Pharmacol* 36:3801, 1987.
- [101] Sies, H. Oxidative stress: Introductory remarks. In: Sies, H. Oxidative stress; London, Academic Press, 1, 1985.
- [102] Sluis, K.B., Darlow, B.A., George, P.M., Mogridge, N., Dolamore, B.A., Winterbourn, C.C. Selenium and glutathione peroxidase levels in premature infants in a low selenium community (Christchurch, New Zealand). *Pediatr Res* 32:189, 1992.
- [103] Srivastava, S. K., Beutler, E. Accurate measurement of oxidized glutathione content of human, rabbit, and rat red blood cells and tissues. *Anal Biochem* 25:70-76, 1968.

- [104] Stephenson, L.S., Latham, M.C., Ottesen, E.A. Global malnutrition. *Parasitology* 121: 5, 2000.
- [105] Stone, W.L. Henderson, R. A., Howard, G.H., Hollis, A.L., Payne, P.H., Scott, R.L The role of antioxidant nutrients in preventing hyperbaric oxygen damage to the retina. *Free Rad Biol Med* 6:505, 1989.
- [106] Sullivan, L.J. Iron, plasma antioxidants, and the oxygen radical disease of prematurity. *Am J Dis Child* 142: 1341, 1988.
- [107] Sullivan, J. L. Retinopathy of prematurity and iron: a modification of the oxygen hypothesis. *Pediatrics* 78: 1171, 1986.
- [108] Suttorp, N., Kastle, S., Neuhof, H. Glutathione redox cycle is an important defense system of endothelial cells against chronic hyperoxia. *Lung* **169**:203, 1991.
- [109] Szabo, G., Balint, Sz., Nyeste, E. Trace element deficiency in healthy subjects based on multi-element analysis of serum and plasma. *Orv Hetil* 132: 395, 1991.
- [110] Szebeni, J., Winterbourn, C.C., Carrell R. W. Oxidative interactions between haemoglobin and membrane lipid. A liposome model. *Biochem J* 220: 685, 1984.
- [111] Takahashi, K., Cohen, H.J, Selenium-dependent glutathione peroxidase protein and activity: immunological investigations on cellular and plasma enzymes. *Blood* **68**:640, 1986.
- [112] Takahashi, K., Newburger, P.E., Cohen, H.J. Glutathione peroxidase protein. Absence in selenium deficiency states and correlation with enzymatic activity. *J Clin Invest* 77:1402, 1986.
- [113] Terry, T. L. Extreme prematurity and fibroplastic overgrowth of persistent vascular sheath behind each crystalline lens. A preliminary report. *Am J Ophthalmol* 25: 203, 1942.

- [114] The Committee for the Classification of Retinopathy of Prematurity.

 An international classification of retinopathy of prematurity.

 Pediatrics 74:127, 1984.
- [115] Thorling, E.B., Overvad, K., Geboers, J. Selenium status in Europehuman data. A multicenter study. *Ann Clin Res* 18:3, 1986.
- [116] Thornalley, P. J., McLellan, A. C., Lo, T. W. C., Sönksen, P. H. Negative association between erythrocyte reduced glutathione concentration and diabetic complications. *Clin Sci* **91**:575, 1996.
- [117] Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Application to mammalian blood and other tissues. *Anal Biochem* 27:502, 1969.
- [118] Tyson, J.E., Wright, L.L., Oh, W., Kennedy, K.A., Mele, L., Ehrenkranz, R.A., Stoll, B.J., Lemons, J.A., Stevenson, D.K, Bauer, C.R., Korones, S.b., Fanaroff A.A. Vitamin A supplementation for extermely-low birth weight infants. N Engl J Med. 340:1962, 1999.
- [119] Tzimas, G., Nau, H. The role of metabolism and toxokinetics in retinoid teratogenesis. *Curr Pharm Des* 7: 803, 2001.
- [120] Ursini, M. V.; Parrella, A.; Rosa, G.; Salzano, S.; Martini, G. Enhanced expression of glucose-6-phosphate dehydrogenase in human cells sustaining oxidative stress. *Biochem J* 323:801-806; 1997
- [121] Valentine, P. H., Jackson, J.C., Kalina, R.E., Woodrum, D.E. Increased survival of low birth weight infants: impact on the incidence of retinopathy of prematurity. *Pediatrics* 84:442, 1989.
- [122] Voyles, L.M., Turner, R.e., Lokowski, M.J., Langkamp-Henken, B. High levels of retinol intake durig the first trimester of pregnancy as a result from use over he counter vitamin/mineral supplements. *J Am Diet Assoc* 100: 1068, 2000.
- [123] Winterbourn C.C., Chan, T., Buss, I.H., Inder, T.E., Mogridge, N., Darlow, B.A. Protein carbonyls and lipid peroxidation products as

- oxidation markers in preterm infant plasma: associations with chronic lung disease and retinopathy and effects of selenium supplementation. *Pediatr Res* **48**:84, 2000.
- [124] Winterbourn, C. C. Oxidative reactions of hemoglobin. *Methods Enzymol* **186**:265, 1990.
- [125] Yoshida, A. Hemolytic anaemia and G6PD deficiency. *Science* 179:532, 1973.
- [126] Zachara, B. A., Dobrynski, W., Trafikowska, U., Szymanski, W. Blood selenium and glutathione peroxidases in miscarriage. *BJOG* 108:244, 2001.
- [127] Zhu, L. The antioxidative ability of erythrocyte of children with different selenium status. *Acta Pharmacol Toxicol* **59:**331, 1986.